非酒精性脂肪性肝病合并2型糖尿病患者血清抵抗素和黄醇结合蛋白4水平及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2022.02.020

Abstract

Abstract: Objective The aim of this study was to explore the implication of serum resistin and retinol-binding protein 4 (RBP4) in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Methods 106 patients with NAFLD and T2DM and 106 patients with NAFLD were enrolled in our hospital between October 2017 and January 2021,and blood lipid and fasting blood glucose (FBG) levels were detected by full-automatic biochemical analyzer. Serum fasting insulin (FINS) level was detected by chemiluminescence, and the pancreatic β-cell function was assessed by HOMA-β. The insulin resistance (IR) was assessed by homeostasis model assessment (HOMA-IR). Serum resistin, RBP4, tumor necrosis factor (TNF-α) and interleukin (IL-6) levels were detected by ELISA. Results Total serum cholesterol and high-density lipoprotein cholesterol levels in patients with NAFLD and T2DM were (4.7±0.5)mmol/L and (1.1±0.2)mmol/L, significantly lower than [(5.6±0.6)mmol/L and (1.4±0.3)mmol/L, respectively, P<0.05] in patients with NAFLD; serum gamma-glutamyl transferase level in patients with NAFLD and T2DM were (102.3±15.5)U/L, significantly higher than [(71.6±4.6), P<0.05] in patients with NAFLD, while there were no significant differences as respect to serum alanine aminotransferase, aspartate aminotransferase and aLkaline phosphatase levels between the two groups (P>0.05); the FBG, FINS and HOMA-IR in patients with NAFLD and T2DM were (7.7±0.8)mmol/L, (6.7±1.2)mU/L and (2.3±0.5), significantly higher than [(5.7±0.7)mmol/L, (5.5±2.3)mU/L and (1.4±0.2), respectively, P<0.05], while the HOMA-β was (3.7±0.4), significantly lower than [(5.0±0.5), P<0.05] in patients with NAFLD; serum resistin, RBP4, TNF-α and IL-6 levels in patients with NAFLD and T2DM were(3.2±0.4)ng/mL, (57.3±12.3)mg/L, (376.2±36.7)pg/mL and (76.3±8.2) ng/L, significantly higher than [(1.2±0.2)ng/mL, (32.7±7.1)mg/L,(340.3±38.2)pg/mL and (68.4±7.6)ng/L, respectively, P<0.05] in patients with NAFLD. Conclusion There are differences in liver function indexes, glucose metabolism indexes, resistin , RBP4 and cytokine levels between patients with NAFLD and T2D and those with NAFLD alone, which might help distinguish the two entity in clinical practice.

Key words: Non-alcoholic fatty liver diseases, Type 2 diabetes mellitus, Resistin, Retinol-binding protein 4, Sera

Mo Chaoyan, Yang Youqiang, Zhong Yuan, et al. Implication of serum resistin and retinol-binding protein 4 in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus[J]. Journal of Practical Hepatology, 2022, 25(2): 231-234.

References

[1] Maurice J,Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond), 2018,18(3):245-250.
[2] Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci, 2018,75(18):3313-3327.
[3] Javeed N, Matveyenko AV. Circadian etiology of type 2 diabetes mellitus. Physiology (Bethesda), 2018,33(2):138-150.
[4] Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol, 2018, 14(2):88-98.
[5] Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects ofdapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab, 2019, 21(2):285-292.
[6] Tripathi D, Kant S, Pandey S, Ehtesham NZ. Resistin in metabolism, inflammation, and disease. FEBS J, 2020, 287(15):3141-3149.
[7] Zhang YP, Deng YJ, Tang KR, et al. Berberine ameliorates high-fat diet-induced non-alcoholic fatty liver disease in rats via activation of SIRT3/AMPK/ACC pathway. Curr Med Sci, 2019, 39(1):37-43.
[8] Moraes-Vieira PM, Yore MM, Sontheimer-Phelps A, et al. Retinol binding protein 4 primes the NLRP3 inflammasome by signaling through Toll-like receptors 2 and 4. Proc Natl Acad Sci U S A, 2020,117(49):31309-31318.
[9] Wang X, Chen X, Zhang H, et al. Circulating retinol-binding protein 4 is associated with the development and regression of non-alcoholic fatty liver disease. DiabetesMetab, 2020, 46(2):119-128.
[10] 中华医学会糖尿病学分会. 中国T2DM防治指南(2013年版). 中华内分泌代谢杂志, 2014, 30(8):893-942.
[11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[12] Safari Z, Gérard P. The links between the gutmicrobiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci, 2019,76(8):1541-1558.
[13] 毛重山, 殷辉, 肖二辉, 等. 非诺贝特对NAFLD合并T2DM患者血脂、血管内皮功能和肝纤维化指标的影响. 实用肝脏病杂志, 2020, 23(1):50-53.
[14] Rashidmayvan M, Mohammadshahi M, Seyedian SS, et al. The effect of Nigella sativa oil on serum levels of inflammatory markers, liver enzymes, lipid profile, insulin and fasting blood sugar in patients with non-alcoholic fatty liver. J Diabetes Metab Disord, 2019,18(2):453-459.
[15] Zhou L, Wang SB, Chen SG, et al. Prognosticvalue of ALT, AST, and AAR in hepatocellular carcinoma with B-type hepatitis-associated cirrhosis after radical hepatectomy. Clin Lab, 2018,64(10):1739-1747.
[16] Yang JM, Sun Y, Wang M, et al. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World JGastroenterol, 2019, 25(34):5105-5119.
[17] Sattari M, Bril F, Egerman R, et al. Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy. J Investig Med, 2020,68(3):743-747.
[18] Mohapatra E, Priya R, Nanda R, et al Serum GGT and serum ferritin as early markers for metabolic syndrome. J Family Med Prim Care, 2020,9(7):3458-3463.
[19] Akbulut UE, Emeksiz HC, Citli S, et al. IL-17A, MCP-1, CCR-2, and ABCA1 polymorphisms in children with non-alcoholic fatty liver disease. J Pediatr (Rio J), 2019, 95(3):350-357.
[20] Gołąbek KD, Regulska-Ilow B. Dietary support in insulin resistance: An overview of current scientific reports. Adv Clin Exp Med, 2019 , 28(11):1577-1585.
[21] Adeva-Andany M, Souto-Adeva G, Ameneiros-Rodríguez E, et al. Insulin resistance and glycine metabolism in humans. Amino Acids, 2018, 50(1):11-27.
[22] Veres A, Faust AL, Bushnell HL, et al. Charting cellular identity during human in vitro β-cell differentiation. Nature, 2019,569(7756):368-373.
[23] Elosua-Bayés I, Beloqui Ruiz Ó. Association between nonalcoholic fatty liver disease, metabolic and vascular risk. Clin Investig Arterioscler, 2020,32(5):200-205.
[24] Fedders R, Muenzner M, Weber P, et al. Liver-secreted RBP4 does not impair glucose homeostasis in mice. J Biol Chem, 2018,293(39):15269-15276.
[25] El-Ashmawy HM, Ahmed AM. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. Eur J Gastroenterol Hepatol, 2019,31(7):859-864.
[26] Chen Y, Ma K. NLRC4inflammasome activation regulated by TNF-α promotes inflammatory responses in nonalcoholic fatty liver disease. Biochem Biophys Res Commun, 2019, 511(3):524-530.

Implication of serum resistin and retinol-binding protein 4 in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liang Yebei, Yang Chunguang, Wang Kunfeng, et al. Epidemiologic investigation of non-alcoholic fatty liver diseases in whole adults of Blang ethnicity in Yunnan province [J]. Journal of Practical Hepatology, 2022, 25(2): 223-226.
[2]	Huang Die, Tian Haoyu, Li Yiling. Serum markers in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 297-300.
[3]	Ren Jie, Hao Qiaoyun, Huang Chenghe, et al. Structure of intestinal flora changes in patients with non-alcoholic fatty liver disease and diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(1): 54-57.
[4]	Ge Haiyan, Kuang Xia, Zhou Ruijun. Changes of serum miR-17, miR-20a and miR-20b levels in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2021, 24(5): 697-700.
[5]	Xu Xiangtao, Qiao Fei, Che Junyong, et al. Short-term efficacy of Huazhuo Tongyu decoction in the treatment of patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(5): 701-704.
[6]	Hao Xiaowei, Bai Na, Guo Xiaojun, et al. Correlationof serum adipocyte type fatty acid binding protein levels to glucose-lipid metabolism in patients with chronic hepatitis C and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 347-350.
[7]	Zhang Yan, Xia Wenfang, Jin Jin, et al. Short-term observation ofglicladine and insulin aspart 50 in the treatment of patients with non-alcoholic fatty liver diseases and hepatogenic diabetes [J]. Journal of Practical Hepatology, 2021, 24(2): 240-243.
[8]	SUN Lina, Gu Jing. Serum ferritin levels in patients withnon-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2021, 24(2): 294-296.
[9]	Xia Shujing, Zhang Lili, Zhang Xiumei, et al. Diagnosticvalue of serum syndecan-4 in patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 43-46.
[10]	Liang Xiaoli,Kuang Jisun,Liu Qiuli,et al. Therapeutic efficacy of fenofibrate at base of calorie restriction diet in the treatment of patients with non-alcoholic fatty liver disease and type 2 diabetes [J]. Journal of Practical Hepatology, 2021, 24(1): 51-54.
[11]	Zhao Xiaochun,Zhong Qing,Liu Shuhong,et al. Changes and clinical implication of serum uric acid levels in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2021, 24(1): 55-58.
[12]	Li Junying, Zhou Ling, Chen Jinjun. Surveillance and management of individuals with high risk of NAFLD [J]. Journal of Practical Hepatology, 2020, 23(5): 612-614.
[13]	Hou Guanghua, Hu Qijiang, Xu Meihua , et al. Short-term efficacy of polyene phosphatidylcholine combined with metformin and fenofibrate in patients with NAFLD [J]. Journal of Practical Hepatology, 2020, 23(4): 528-531.
[14]	Jia Chen, Zhang Tao, Wang Hao, et al. Efficacy of liraglutide in treatment of patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2020, 23(2): 203-206.
[15]	Liu Jiguo, Dou Cuiyun , Cheng Guangling. Changes of blood glycosylated hemoglobin and thyroid hormone levels in patients with NAFLD complicated by T2DM [J]. Journal of Practical Hepatology, 2020, 23(2): 207-210.